Sarepta Therapeutics CEO and Leadership

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

After more than fifteen years of managing a portfolio on the buyside, Ian joined Sarepta for one reason: To have a direct and lasting impact on patient lives. He understands the importance of market access and the vast possibilities of science to ensure no patient is left behind in what is, as he believes, the golden age of 21st Century medicine.

The driving force behind his work at Sarepta as Chief of Staff to the CEO and head of corporate affairs (which includes investor relations [IR] and program management) is shaping a message and a strategy that makes certain the patient remains at the center of every decision. He was a chief architect of Sarepta’s business model and drives the Company’s annual strategic planning process. He also serves as a member of the Company’s Executive Committee.

Ian leverages his financial (15 years on Wall Street as a biotech investor) and scientific (graduating with honors from Columbia University with a B.A. in Psychology-neuroscience, concentration in pre-medicine) acumen to lead Sarepta’s nationally recognized investor relations function, supporting a valuation that increased by more than 1000% during his tenure.

In a 2017 speech delivered during the opening ceremony of Sarepta’s Andover, Massachusetts facility, he called on the audience to appreciate the profound moment in time for biomedical innovation and highlighted the importance the 21st Century Cures Act (of which Sarepta was part author) to ensure innovation continues for not only this generation of patients, but those generations to come.

Ranked #1 Best IR Professional Midcap by Institutional Investor as part of its 2019 All-Americas Team Rankings, under Ian’s leadership, it’s Investor Relations program received a total of 9 total top rankings on the list.

Renowned for her work in neuromuscular biology and gene therapy, Dr. Rodino-Klapac was head of the laboratory for gene therapy research for muscular dystrophies at Nationwide Children’s Hospital prior to joining Sarepta. From July 2010 to June 2018, Dr. Rodino-Klapac was an Associate Professor, Department of Pediatrics, The Ohio State University College of Medicine and Principal Investigator, Center for Gene Therapy for The Research Institute at Nationwide Children's Hospital and a faculty member of the Biomedical Sciences Graduate Program and Molecular, Cellular, and Developmental Biology Graduate Programs, The Ohio State University College of Medicine. Dr. Rodino-Klapac also served as the Ruth L. Kirschstein F32 Post-doctoral Fellow, National Institutes of Health, The Research Institute at Nationwide Children's Hospital; and was a post-doctoral researcher, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital. In February 2017, Dr. Rodino-Klapac co-founded Myonexus Therapeutics, Inc., a clinical stage gene therapy biotech company focused on treatment of Limb girdle muscular dystrophy (LGMD). Dr. Rodino-Klapac serves as acting chief scientific officer of Myonexus and in early May 2018, Sarepta announced a collaboration with Myonexus to develop potentially transformative gene therapies to treat five distinct forms of LGMD. Dr. Rodino-Klapac is the recipient of numerous awards, including the Forty Under 40 Award by Columbus Business First, and the Department of Pediatrics Outstanding Junior Faculty Award for Innovation. She’s the author of numerous publications, among them papers published in The New England Journal of Medicine, Annals of Neurology, and Pediatric Neurology. Dr. Rodino-Klapac received her bachelor’s degree in biology from Kings College, and a Ph.D. in molecular genetics from The Ohio State University.

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.